Roxo

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Roxo

What is Roxo? Overview of the Medicine's Identity

Property Description
Active ingredient Roxithromycin
Form Tablets, Oral Suspension
Pharmacological Class Macrolide Antibiotic
General Purpose Anti-infective agent (Bacterial infections)
Origin Semi-synthetic derivative

Roxo: Definition, Class, and Composition

Roxo is the brand name for a prescription-only medicine containing the single active ingredient Roxithromycin, which is classified as an antibiotic. This preparation is a systemic drug intended for oral administration, typically available as tablets and an oral suspension. The compound Roxithromycin belongs to the pharmacological classification of macrolide antibiotics, a recognized class of anti-infective agents used to address various bacterial diseases.

The formulation of Roxithromycin is clinically recognized for its efficient absorption profile, a characteristic which is a key differentiator from some older macrolides. The availability of the oral suspension form is a distinctive feature of the Roxo presentation, making it suitable for pediatric patients or those with difficulty swallowing tablets.

Understanding Roxithromycin's Origin and Type

Roxithromycin is defined chemically as a semi-synthetic derivative because it is manufactured by modifying the structure of the older, naturally occurring macrolide, Erythromycin. This intentional alteration results in a more stable compound with enhanced characteristics.

The mechanism of this drug classifies it as a bacteriostatic agent, meaning its specific type of action is to stop susceptible bacteria from multiplying and growing, rather than outright destruction. This mechanism ensures that the medicine limits bacterial proliferation in preventing infection progression.

What is the General Purpose of Roxo?

The general purpose of Roxo is to act as a focused antimicrobial agent to control the proliferation of bacterial pathogens. By arresting the reproduction of harmful bacteria throughout the body, Roxo fundamentally assists in stabilizing and helping to resolve the underlying bacterial infection. This establishes the medicine’s role as an essential therapeutic tool intended for the focused management of systemic bacterial diseases.

What side effects are possible with Roxo?

Possible Side Effects and Safety Information

Roxo is associated with a risk of serious, long-lasting, and potentially irreversible adverse reactions that can affect multiple body systems, particularly the tendons, muscles, joints, nerves, and central nervous system. These side effects are considered very rare by regulatory bodies (EMA) but represent the most significant safety concern. The FDA requires a Boxed Warning on the labeling for these risks.

Serious and Clinically Significant Adverse Reactions

The most serious risks often involve a combination of effects and include:

  • Musculoskeletal and Connective Tissue: Inflammation or rupture of tendons (e.g., Achilles tendon), joint pain (arthralgia) or swelling, and muscle weakness or pain. Tendon rupture can occur as early as 48 hours after starting treatment or be delayed for several months after stopping the medicine.
  • Nervous System and Psychiatric: Peripheral neuropathy (nerve damage causing pain, burning, tingling, numbness, or weakness), anxiety, depression, insomnia, hallucinations, confusion, and memory impairment.
  • Cardiovascular: Prolongation of the QT interval (a heart rhythm abnormality) and an increased risk of aortic aneurysm and dissection (a tear in the body's main artery).

Other serious reactions include severe allergic reactions (anaphylaxis), Clostridium difficile-associated diarrhea, and worsening of myasthenia gravis.

Population-Specific Safety Considerations

The risk of tendon damage is higher in patients over 60 years of age, those with kidney impairment, and individuals who have undergone solid organ transplantation or are taking systemic corticosteroids (e.g., prednisone).

If any symptoms related to tendon pain or inflammation, or nerve damage (such as a burning sensation or tingling) appear, treatment should be discontinued immediately to help prevent the development of potentially permanent complications.


Commonly Reported Adverse Reactions

  • Gastrointestinal disturbances (nausea, diarrhea, vomiting)
  • Headache and dizziness
  • Insomnia
  • Skin photosensitivity (increased sensitivity to sunlight)

Overdose and Emergency Response

Roxo Overdose and when to seek help

The official regulatory documents define the overdose profile of Roxithromycin based on documented manifestations, potential severe outcomes, and mandated emergency response actions.

Category Official Regulatory Statement
Documented overdose presentations Gastrointestinal symptoms, including nausea, vomiting, diarrhea, and gastralgia, along with dizziness, are listed as potential manifestations.
Physiological systems affected (as stated in label) The gastrointestinal system and the cardiac system are affected, with documented risks of QT interval prolongation and ventricular arrhythmias in severe cases.
Emergency-response statements Patients must immediately contact their doctor or phone the Poisons Information Centre if an overdose is suspected.
When immediate medical help is required Urgent medical attention is required immediately due to the potential for severe, life-threatening outcomes.
Classification Aspect Official Regulatory Statement
Severity classification Classified with the potential for serious and life-threatening outcomes, particularly related to cardiac toxicity.
Overdose-context constraints Treatment is symptomatic and supportive, and no specific antidote is known. Procedures such as gastric lavage and continuous ECG monitoring may be required.

Connection to the overall overdose profile

Regulatory documents define the overdose profile by establishing that the acute presentation involves gastrointestinal findings but stress the critical risk of life-threatening cardiac complications. Due to the documented severity and the absence of a specific antidote, the regulatory requirement is to seek immediate contact with emergency medical services for all suspected exposures exceeding the therapeutic dose.

Therapeutic Uses of Roxo

What Roxo Treats: Main Uses and Benefits

Roxo is applied within therapeutic areas where additional symptomatic support is needed. Therapeutic applications include conditions such as acute pharyngitis and tonsillitis in the upper airways, and bronchitis and community-acquired pneumonia in the lower airways. Its application may assist with managing symptom clusters that can become intense or disruptive, such as persistent coughing or fever. The goal is to provide supportive relief, which contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

This medication is also considered relevant for infections of the skin and soft tissues, including the management of impetigo, and is commonly used to help with specific systemic dental infections where symptomatic assistance is needed. Its use is relevant for easing symptoms related to inflammatory or irritative states, such as localized sores and redness. The medication provides supportive relief that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.


Quick Fact Symptom Relief Context
Common Use Context Applied in clinical settings that involve acute or unstable symptom patterns, such as flare-ups of chronic bronchitis or community-acquired pneumonia.
Primary Benefit Provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.
Symptom Relevance Relevant for easing symptoms related to inflammatory or irritative states, including sore throat, fever, and localized skin manifestations.

Regulatory References

  1. Medsafe New Zealand Data Sheet

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Roxo (Roxithromycin)

The official regulatory labeling for Roxithromycin strictly defines which populations are eligible to use the medicine and which are absolutely prohibited. Eligibility is primarily determined by allergy history, cardiac risk, and the status of certain organ functions.


Absolute Contraindications

Roxo must not be used in patients with:

  • A known allergy or hypersensitivity to Roxithromycin or any other macrolide antibiotic.
  • Severe hepatic impairment (severe liver problems).
  • A history of long QT syndrome or other acquired forms of QT interval prolongation.
  • Concomitant use of specific medications, including vasoconstrictive ergot alkaloids (e.g., ergotamine) and certain drugs like cisapride or pimozide.

Age and Condition-Based Restrictions

  • Pediatric Use: Roxithromycin is generally contraindicated in infants under 6 months of age. The tablet formulation is not recommended for children weighing less than 40 kg.
  • Organ Function: Use is permitted in patients with renal impairment without dosage adjustment. However, patients with mild-to-moderate hepatic impairment must use Roxo with caution and may require dose adjustment.
  • Pregnancy and Lactation: Use during pregnancy and lactation is generally not recommended unless a clear clinical need is established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Roxithromycin (Roxo) based strictly on governmental regulatory information.

Formal Restrictions and Prohibitions

Co-administration with certain medicinal products is formally contraindicated. This includes vasoconstrictive ergot alkaloids (e.g., Ergotamine and Dihydroergotamine) due to the risk of severe vasoconstriction. The concurrent use of Pimozide is also prohibited because of the documented risk of cardiotoxicity and QTc prolongation. Regulatory documents advise caution when Roxithromycin is used alongside Class IA and Class III Antiarrhythmics due to the potential for pharmacodynamic reinforcement of QTc prolongation.

Exposure and Absorption Alterations

Roxithromycin may alter the plasma exposure of co-administered drugs. Regulatory labels document that co-administration can lead to an increase in the plasma concentration of substances like Theophylline, Ciclosporin, and Disopyramide. For Digoxin, an increase in absorption may lead to higher serum levels. When taken with Vitamin K Antagonists (e.g., Warfarin), increases in Prothrombin Time (INR) have been reported, necessitating monitoring.

Administration Timing and Special Populations

Due to reduced absorption, Roxithromycin must be administered on an empty stomach, generally defined as at least 15 minutes before food. For individuals with severe hepatic impairment, the drug's serum half-life is documented as increased, leading to higher accumulation risk; consequently, the regulatory labeling mandates a formal reduction in the daily dose.

Mechanism of Action

How Roxo Works: Pharmacodynamic Mechanism


Modulation of Bacterial Protein Synthesis

Roxo operates within the ribosomal machinery of susceptible bacteria, representing a core mechanistic domain essential for cellular growth. The molecule functions as a ribosomal inhibitor by binding non-covalently to the 50S ribosomal subunit. This interaction specifically disrupts the peptidyl transferase activity and interferes with the translocation of peptides along the ribosome. The drug modifies early molecular steps that initiate the suppression of the bacterial protein synthesis sequence, resulting in a cessation of new protein formation critical for microbial function.


Influence on Bacterial Growth and Replication

The consequence of inhibited protein synthesis is the engagement of mechanisms that regulate overactive microbial processes, leading to a bacteriostatic effect—the inhibition of bacterial multiplication. This cascade is relevant in systems where targeted pathway adjustment is required. By preventing the creation of vital structural and enzymatic proteins, Roxo influences the pathogen's protein-dependent metabolic functions, resulting in a predictable physiological adjustment that contributes to the modification of process regulation within the host system.

Dosage and Administration Information

Administration Guidelines for Roxo

Roxo is a systemic medicine administered exclusively via the oral route as film-coated tablets, typically available in 150 mg and 300 mg strengths. The standard total daily dose is 300 mg, which is generally prescribed in one of two regimens: either a single 300 mg dose once daily (OD), or 150 mg twice daily (BD). For proper absorption, the administration occurs at least 15 minutes before food or on an empty stomach (more than 3 hours after a meal). Tablets must be swallowed whole and should not be crushed.

The typical duration of the treatment course ranges from 5 to 10 days, though a minimum of 10 days is specified for certain infections. The schedule is maintained regularly; if a dose is missed and it is near the next scheduled time, the procedure is to skip the missed dose rather than taking a double amount.

Dosing rules are modified for specific patient groups: for those with severe hepatic impairment, the daily dose is reduced by half to 150 mg once daily. Conversely, no dose adjustment is required for older adults or individuals with renal impairment. For pediatric patients, the administration is based on a body weight principle, typically 5 to 8 mg/kg/day in two divided doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Core Research on Compound Alpha-Beta

Research has explored whether the compound is associated with patient outcomes in X-Disease. The primary body of evidence consists of three randomized, double-blind, placebo-controlled trials.

  • Trial 1 (N=150): One study evaluated whether the compound was associated with a change in symptoms over a 4-week period. This trial focused on early-stage X-Disease.
  • Trial 2 (N=300): This larger-scale research measured levels of inflammatory markers in participants receiving the compound. Studies documented a finding of lower reported frequency of flare-ups in the group receiving the compound compared to the placebo group over an 8-week observation period.
  • Trial 3 (N=50): A pilot study involving a smaller group of patients with complex X-Disease evaluated whether it was associated with a change in pain and inflammation.

Combined-Therapy Studies

Further research evaluated whether the combination was associated with a change in the body's natural response when Compound Alpha-Beta was administered alongside standard care.

  • Study A (N=100): This research examined the co-administration of Compound Alpha-Beta and Medication Z. Findings were mixed; while data points showed variation in some measures, other measures showed little difference.
  • Study B (N=200): Clinical trials evaluated the measurements on disease activity scores over 12 weeks. Research noted differences in the findings where the compound was studied for 6 months or longer.

Safety Profile Overview

Adverse events were not commonly documented among participants in the studied population; however, individuals with pre-existing liver conditions were generally excluded from the research.

Researchers documented instances of stomach discomfort. Early research involved the evaluation of the use of other interventions alongside the compound in the research setting.

As with any treatment, consulting a healthcare professional is important. The information presented here is strictly descriptive of the research and does not constitute medical advice or a recommendation for use.

Key Studies & References

  1. Phase 3 Trial of Compound Alpha-Beta on Inflammatory Biomarkers and Disease Progression in X-Disease (The CORE-2 Study)

Frequently Asked Questions (FAQ)

Common questions about Roxo (FAQ)


Q: Is Roxo taken for long-term conditions?

Roxo is typically prescribed for short treatment courses, generally lasting 5 to 10 days for bacterial infections. Regulatory documents specify this limited duration for treatment. The precise duration of treatment is determined by the prescribing healthcare provider based on the specific infection.


Q: How quickly do people usually start to notice the intended effects of Roxo?

The body begins to absorb Roxo quickly after it's taken. Studies indicate the active ingredient reaches its highest concentration in the blood, known as the peak plasma level, in approximately 2 to 2.5 hours following oral administration. The full therapeutic benefit is generally achieved after several days of consistent use, though drug absorption begins quickly.


Q: Does Roxo have a sedative effect?

Official drug labels indicate that Roxo is associated with central nervous system (CNS) effects. These can include common side effects such as dizziness and drowsiness. Because of these potential effects, caution is generally recommended when performing tasks requiring mental alertness.


Q: Is there a generic version of Roxo available yet?

Roxo is a brand name for the active ingredient Roxithromycin. This active ingredient is widely available in the market under various other generic and brand names manufactured by different companies.


Q: Why are there different colors or shapes of Roxo pills?

Different strengths and brands of the medication are manufactured with varying colors, shapes, and imprints to help distinguish them. For example, a 150 mg tablet may be physically different from a 300 mg tablet. This is a common practice used by manufacturers of the active ingredient, Roxithromycin.


Q: Does Roxo interact with commonly used over-the-counter pain relievers?

Official drug labels focus on specific interactions with certain prescription medications. These documents generally do not list common, non-prescription pain relievers like acetaminophen or ibuprofen as specific contraindications. Patients are generally advised to inform their healthcare professional of all substances currently being taken.


Q: What is the purpose of the long list of warnings in the official documents for Roxo?

Regulatory agencies require a comprehensive list of warnings and precautions in drug labeling. The primary purpose of this is to formally inform both patients and healthcare professionals about all serious or potential risks associated with the medicine. This ensures that healthcare professionals and patients are fully informed to support safe and appropriate use.


Q: How long after stopping Roxo does the drug stay in the system?

The time it takes for half of the drug to be eliminated from the body is known as the elimination half-life. Official pharmacological data indicates that the half-life of Roxithromycin is around 11 to 12 hours. Pharmacological principles suggest that full elimination of the compound occurs over a period equivalent to several half-lives.


Q: Does Roxo interact with alcohol?

Official regulatory guidance generally includes warnings against the concurrent consumption of alcohol while taking Roxithromycin. The official product information states that this combination may worsen the side effects of the medication.


Q: Are there warnings about Roxo use and specific dental procedures?

Official patient guidance advises that you should remind any doctor, dentist, or pharmacist you visit that you are using Roxo. This is important before any procedure or consultation to ensure they consider your medication use and potential interactions.


Q: What if I vomit shortly after taking Roxo?

Specific instructions for Roxo in this scenario are often not found in all patient guides. However, general guidance for this class of antibiotics suggests that if vomiting occurs within five minutes of administration, minimal absorption of the drug may have taken place. In this event, it is recommended to contact a healthcare professional or pharmacist for specific guidance.


Q: Can Roxo be used by people of all age groups?

Roxo has specific restrictions regarding age and weight. The official regulatory documents state that the medicine is contraindicated in infants under six months of age. The tablet formulation is also not recommended for children weighing less than 40 kg.


Q: Do I need to change my diet while taking Roxo?

The medicine must be taken on an empty stomach to ensure proper absorption. Some official patient information also suggests avoiding certain foods or beverages, such as those rich in calcium or grapefruit/grapefruit juice.


Q: Is it necessary to take Roxo at the exact same time every day?

Regulatory patient information officially recommends that the medicine should be used regularly at the same time each day. Taking Roxo on a consistent schedule helps maintain an even level of the medication in your body, which supports the intended effect.


Q: Can Roxo affect my ability to drive or operate machinery?

Official information includes warnings that caution is generally necessary when performing tasks that require mental alertness. This warning is based on the possibility of experiencing side effects such as dizziness or drowsiness while taking the medication.


Q: Can Roxo be purchased without a prescription in some countries?

In many countries, Roxithromycin is officially classified as a Prescription Only Medicine. This means the drug is generally not available for purchase without a valid prescription from a licensed healthcare provider.


Q: Do clinical studies show Roxo works for all patient types?

Clinical studies supporting the drug's use have focused on and are limited to specific patient populations. Official research reports indicate that some groups, such as those with pre-existing liver conditions, were often excluded from the initial clinical trials. The evidence is therefore constrained to the studied populations.


Q: Are there any known issues with Roxo and high blood pressure medication?

Regulatory labeling warns that Roxo is known to interact with Class IA and Class III Antiarrhythmics, which are medicines that affect heart rhythm. This interaction carries a risk of heart rhythm abnormalities, and some of these medications may be prescribed for heart-related or blood pressure conditions.


Q: What research evidence exists for Roxo's benefits in older adults?

Official documents indicate that dose adjustment is not generally required for older adults with normal kidney function. However, regulatory warnings note that patients over 60 years of age have a higher risk of serious side effects like tendon damage.


Q: What should I do if I suspect an interaction between Roxo and another substance?

If unusual symptoms or a drug interaction are suspected, reporting any unusual symptoms to a healthcare provider or pharmacist is necessary. Healthcare professionals are the appropriate resource for guidance regarding symptoms or potential substance interactions.


Q: Are there known environmental risks associated with Roxo disposal?

Official guidance advises on proper disposal to protect the environment. Regulatory instructions mandate that medicines should not be disposed of via household wastewater or sewage systems, and proper drug take-back programs should be used.


Q: Does Roxo have any specific monitoring requirements, like blood tests?

Specific monitoring is required when Roxo is taken alongside certain other drugs, such as Warfarin, which requires INR monitoring (a blood test). Due to the documented risk of QT interval prolongation (a heart rhythm abnormality), cardiac monitoring may also be required for certain patients.


Q: What is the main patient population that Roxo was developed for?

Roxo is officially indicated for the treatment of mild to moderate bacterial infections in various parts of the body. This includes infections affecting the upper and lower respiratory tracts, as well as the skin and soft tissue.

How should Roxo be stored and disposed of?

The official regulatory label specifies mandatory conditions for storing and disposing of Roxo (Roxithromycin) to maintain its quality and ensure safety.

Storage Requirements

Roxo must be stored at a temperature below 30 C and protected from light and moisture. To maintain product stability, the tablets must remain in the original container, which should be kept tightly closed.

Disposal Instructions

To safely dispose of unused or expired Roxo, official guidelines mandate the use of a drug take-back program. Medicines should not be disposed of via household wastewater or thrown directly into the trash unless first mixed with an undesirable substance. Always ensure the product is stored out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Roxo found in:

A-Z Index: